

AMENDMENT UNDER 37 C.F.R. § 1.116 AND REQUEST FOR WITHDRAWAL OF FINALITY OF OFFICE ACTION

Attorney Docket No.: Q93540


Application No.: 10/569,831

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended): A compound represented by formula (IA-2-1):



wherein ring A represents a cyclic group;

ring B represents a dihydronaphthalene group, an indene group, or a 6,7-dihydro-5H-benzo[7]annulene group which may further have a substituent(s);

X represents $-CH_2-$, $-(CH_2)_2-$, $-(CH_2)_3-$, $-(CH_2)_4-$, $-(CH_2)_5-$, $-(CH_2)_6-$, $-(CH_2)_7-$, $-(CH_2)_8-$, $-O-$, $-CH_2-O-$, $-(CH_2)_2-O-$, $-(CH_2)_3-O-$, $-(CH_2)_4-O-$, $-(CH_2)_5-O-$, $-CH=CH-CH_2-O-$ or $-cyclopropylene-CH_2-O-$, which each may be substituted, in which the right side of each group is bound to ring B;

ring D^1 represents a nitrogen-containing heterocyclic group;

Y^{1-3} represents methylene which may have a substituent(s), ethylene which may have a substituent(s), propylene which may have a substituent(s) or propenylene which may have a substituent(s);

R^{27} represents a hydrogen atom, a halogen atom, or C1-4 alkyl which may be substituted with 1 to 3 halogen atoms;

t is 0 or an integer of 1 to 5;

AMENDMENT UNDER 37 C.F.R. § 1.116 AND REQUEST FOR WITHDRAWAL OF FINALITY OF OFFICE ACTION

Attorney Docket No.: Q93540

Application No.: 10/569,831

R¹ represents a substituent of ring A;

n represents 1;

m is 0 or an integer of 1 to 7, and when m is 2 or more, plural R¹s are the same or different;

when X is -O- or -CH₂-O- and ring A is phenyl, m is an integer of ~~1 to 7~~ 1 to 5,
or a salt thereof, or a prodrug thereof.

2 - 4. (canceled).

5. (previously presented): The compound according to claim 1, wherein ring A is a benzene, indane, indene or naphthalene ring.

6 - 15. (canceled).

16. (previously presented): The compound according to claim 1, wherein Y¹⁻³ is -CH₂-, -(CH₂)₂-, or -(CH₂)₃-, which each may be substituted.

17 - 18. (canceled).

19. (previously presented): The compound according to claim 1, wherein the substituent represented by R¹ is a halogen atom, C1-20 alkyl which may be substituted, or C1-20 alkyloxy which may be substituted.

AMENDMENT UNDER 37 C.F.R. § 1.116 AND REQUEST FOR WITHDRAWAL OF FINALITY OF OFFICE ACTION

Attorney Docket No.: Q93540


Application No.: 10/569,831

20. (previously presented): The compound according to claim 19, wherein the substituent represented by R^1 is fluoro, chloro, bromo, methyl, ethyl, propyl, butyl, trifluoromethyl or methoxy.

21. (canceled).

22. (currently amended): The compound according to claim 1, which is a compound represented by

formula (I-S-7a):



wherein R^{S0} , R^{S1} , R^{S2} , R^{S3} , R^{S4} , R^{S5} and R^{S6} each ~~has the same meaning as described above~~ independently represents a hydrogen atom, a halogen atom, or C1-4 alkyl which may be substituted with 1 to 3 halogen atom; R^{S12} , R^{S13} , R^{S14} and R^{S15} each independently represents a hydrogen atom, a halogen atom, or C1-4 alkyl which may be substituted with 1 to 3 halogen atoms; and other symbols have the same meanings as described in claim 1.

23 - 24. (canceled).

AMENDMENT UNDER 37 C.F.R. § 1.116 AND REQUEST FOR WITHDRAWAL OF FINALITY OF OFFICE ACTION

Attorney Docket No.: Q93540

Application No.: 10/569,831

25. (previously presented): The compound according to claim 1, which is
- (11) 1-([1-methyl-6-(4-phenylbutoxy)-3,4-dihydro-2-naphthalenyl]methyl)-3-azetidinecarboxylic acid,
- (14) 1-({6-[3-(4-chlorophenyl)propoxy]-1-methyl-3,4-dihydro-2-naphthalenyl}methyl)-3-azetidinecarboxylic acid, or
- (15) 1-({6-[3-(4-fluorophenyl)propoxy]-1-methyl-3,4-dihydro-2-naphthalenyl}methyl)-3-azetidinecarboxylic acid.
26. (canceled).
27. (currently amended): A pharmaceutical composition which comprises a compound represented by formula (IA-2-1) in claim 1, or a salt thereof, ~~or a prodrug thereof~~.
28. (original): The pharmaceutical composition according to claim 27, which is an S1P receptor binding agent.
29. (original): The pharmaceutical composition according to claim 28, which is an EDG-6 binding agent which may have an ability to bind to EDG-1.
30. (original): The pharmaceutical composition according to claim 29, wherein the EDG-6 binding agent which may have an ability to bind to EDG-1 is an EDG-6 agonist which may have an agonistic activity against EDG-1.

AMENDMENT UNDER 37 C.F.R. § 1.116 AND REQUEST FOR WITHDRAWAL OF FINALITY OF OFFICE ACTION

Attorney Docket No.: Q93540

Application No.: 10/569,831

31. (original): The pharmaceutical composition according to claim 27, which is an agent for preventing and/or treating a disease related to EDG-1 and/or EDG-6.

32. (original): The pharmaceutical composition according to claim 31, wherein the disease related to EDG-1 and/or EDG-6 is rejection in transplantation, autoimmune disease and/or allergic disease.

33. (original): The pharmaceutical composition according to claim 31, wherein the disease related to EDG-1 and/or EDG-6 is rejection in transplantation of kidney, liver, heart, lung, dermal graft, cornea, bone, bone marrow cells and/or pancreatic islet cells, collagen disease, systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, psoriasis, inflammatory bowel disease, Crohn's disease, autoimmune diabetes, lung fibrosis, atopic dermatitis and/or asthma.

34. (original): The pharmaceutical composition according to claim 27, which is an immunosuppressant agent.

35. (original): The pharmaceutical composition according to claim 27, which is an agent causing lymphopenia.

36. (canceled).

AMENDMENT UNDER 37 C.F.R. § 1.116 AND REQUEST FOR WITHDRAWAL OF FINALITY OF OFFICE ACTION

Attorney Docket No.: Q93540

Application No.: 10/569,831

37. (currently amended): A medicament comprising the compound represented by formula (IA-2-1) according to claim 1, or a salt thereof, ~~or a prodrug thereof~~ in combination with one or at least two selected from the group consisting of an antimetabolite, an alkylating agent, a T cell activation inhibitor, a calcineurin inhibitor, a proliferation signal inhibitor, a steroid, an immunosuppressant agent, an antibody used in immune suppression, an agent for treating rejection, an antibiotic, an antiviral agent and an antifungal agent.

38. (currently amended): An immunosuppressant agent and/or an agent causing lymphopenia, which comprises a compound represented by formula (IA-2-1) according to claim 1 or a salt thereof which has an ability to bind to EDG-6 and may have an ability to bind to EDG-1.

39. (original): The immunosuppressant agent and/or the agent causing lymphopenia according to claim 38, which is an agent for preventing and/or treating rejection in transplantation, autoimmune disease and/or allergic disease.

40. (withdrawn-currently amended): A method for treating a disease related to EDG-1 and/or EDG-6 in a mammal, which comprises administering to the mammal an effective amount of the compound represented by formula (IA-2-1) according to claim 1, or a salt thereof, ~~or a prodrug thereof~~.

**AMENDMENT UNDER 37 C.F.R. § 1.116 AND REQUEST FOR WITHDRAWAL OF
FINALITY OF OFFICE ACTION**

Attorney Docket No.: Q93540

Application No.: 10/569,831

41. (withdrawn-currently amended): A method for immune suppression and/or lymphopenia in a mammal, which comprises administering to the mammal an effective amount of the compound represented by formula (IA-2-1) according to claim 1, or a salt thereof, ~~or a prodrug thereof.~~

42-43. (canceled).